Profile data is unavailable for this security.
About the company
AtaiBeckley Inc is a clinical-stage biotechnology company focused on developing rapid-acting, durable and convenient mental health treatments. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.
- Revenue in USD (TTM)3.02m
- Net income in USD-154.19m
- Incorporated2025
- Employees54.00
- LocationAtaiBeckley IncNEW YORK 10119United StatesUSA
- Fax+1 (302) 655-5049
- Websitehttps://www.ataibeckley.com/
More ▼
Mergers & acquisitions
| Acquired company | ATAI:NMQ since announced | Transaction value |
|---|---|---|
| Beckley Psytech Ltd | 59.74% | -- |
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capricor Therapeutics Inc | 11.13m | -81.99m | 1.18bn | 160.00 | -- | 14.09 | -- | 106.14 | -1.80 | -1.80 | 0.2451 | 1.83 | 0.1015 | -- | 47.48 | 69,565.69 | -74.74 | -45.52 | -96.03 | -61.91 | -- | -- | -736.62 | -248.15 | -- | -- | 0.0387 | -- | -11.55 | 85.83 | -81.57 | -- | -- | -- |
| Alvotech SA | 573.35m | 69.50m | 1.18bn | 1.01k | 18.16 | -- | 11.27 | 2.07 | 0.2093 | 0.2093 | 1.93 | -0.5671 | 0.434 | 1.53 | 4.30 | 567,111.80 | 5.26 | -- | 6.38 | -- | 55.59 | -- | 12.12 | -201.24 | 0.7376 | 2.57 | 1.16 | -- | 426.84 | 42.86 | 57.98 | -- | 47.91 | -- |
| Taysha Gene Therapies Inc | 6.31m | -99.93m | 1.24bn | 73.00 | -- | 5.67 | -- | 196.65 | -0.3328 | -0.3328 | 0.0212 | 0.7995 | 0.0254 | -- | -- | 86,438.36 | -40.23 | -70.59 | -45.55 | -88.39 | -- | -- | -1,583.66 | -2,287.96 | -- | -- | 0.1899 | -- | -46.07 | -- | 19.96 | -- | -- | -- |
| Septerna Inc | 22.05m | -58.81m | 1.26bn | 75.00 | -- | 3.23 | -- | 57.13 | -1.51 | -1.51 | 0.5304 | 8.71 | 0.0565 | -- | 4.98 | 293,933.30 | -15.06 | -- | -16.99 | -- | -- | -- | -266.77 | -- | -- | -- | 0.00 | -- | 611.92 | -- | -12,762.79 | -- | -- | -- |
| MoonLake Immunotherapeutics | 0.00 | -227.32m | 1.27bn | 130.00 | -- | 4.15 | -- | -- | -3.52 | -3.52 | 0.00 | 4.27 | 0.00 | -- | -- | 0.00 | -51.05 | -- | -55.64 | -- | -- | -- | -- | -- | -- | -33.78 | 0.1957 | -- | -- | -- | -91.13 | -- | -- | -- |
| Monte Rosa Therapeutics Inc | 181.54m | 20.95m | 1.31bn | 147.00 | 71.68 | 4.51 | 44.73 | 7.21 | 0.2506 | 0.2506 | 2.20 | 3.98 | 0.4685 | -- | 65.30 | 1,354,761.00 | 5.41 | -33.14 | 6.24 | -39.19 | -- | -- | 11.54 | -563.84 | -- | -- | 0.00 | -- | -- | -- | 46.29 | -- | 23.56 | -- |
| Rapport Therapeutics Inc | 0.00 | -97.70m | 1.33bn | 69.00 | -- | 2.59 | -- | -- | -2.71 | -2.71 | 0.00 | 10.74 | 0.00 | -- | -- | 0.00 | -22.55 | -- | -23.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -125.11 | -- | -- | -- |
| AtaiBeckley Inc | 3.02m | -154.19m | 1.34bn | 54.00 | -- | 5.55 | -- | 443.33 | -0.8136 | -0.8136 | 0.0161 | 0.6644 | 0.0138 | -- | 0.3354 | 55,981.48 | -70.56 | -45.69 | -77.07 | -50.03 | -- | -- | -5,104.20 | -2,658.81 | -- | -- | 0.00 | -- | -1.91 | -- | -271.09 | -- | 37.97 | -- |
| Zenas Biopharma Inc | 15.00m | -189.90m | 1.35bn | 130.00 | -- | 5.41 | -- | 90.11 | -12.67 | -12.67 | 0.4565 | 4.65 | 0.0414 | -- | -- | 115,384.60 | -52.35 | -- | -60.38 | -- | -- | -- | -1,265.99 | -- | -- | -116.56 | 0.2709 | -- | -90.00 | -- | -322.87 | -- | -- | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -129.47m | 1.36bn | 104.00 | -- | 3.46 | -- | -- | -1.51 | -1.51 | 0.00 | 3.90 | 0.00 | -- | -- | 0.00 | -37.91 | -36.88 | -40.60 | -39.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1.27 | -- | 1.31 | -- |
| MBX Biosciences Inc | 0.00 | -80.50m | 1.37bn | 43.00 | -- | 3.52 | -- | -- | -3.39 | -3.39 | 0.00 | 8.67 | 0.00 | -- | -- | 0.00 | -23.59 | -- | -24.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -90.16 | -- | -- | -- |
| Vir Biotechnology Inc | 68.56m | -437.99m | 1.42bn | 367.00 | -- | 1.62 | -- | 20.76 | -3.16 | -3.16 | 0.4949 | 5.49 | 0.0571 | -- | -- | 186,801.10 | -36.47 | -5.87 | -40.01 | -6.81 | 99.96 | 92.66 | -638.87 | -18.05 | -- | -- | 0.00 | -- | -7.61 | -2.14 | 16.09 | -- | -5.90 | -- |
| AnaptysBio Inc | 169.47m | -84.63m | 1.46bn | 136.00 | -- | -- | -- | 8.63 | -2.82 | -2.82 | 5.70 | -1.07 | 0.4004 | -- | 3.86 | 1,246,081.00 | -19.99 | -19.96 | -22.14 | -21.08 | -- | -- | -49.94 | -200.59 | -- | -- | 1.10 | -- | 432.03 | 62.73 | 11.24 | -- | -14.96 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -15.08m | 1.47bn | 31.00 | -- | 18.24 | -- | -- | -0.2004 | -0.2004 | 0.00 | 0.961 | 0.00 | -- | -- | 0.00 | -21.65 | -46.71 | -35.55 | -55.72 | -- | -- | -- | -- | -- | -38.28 | 0.00 | -- | -- | -- | -130.47 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to AtaiBeckley Inc's reporting currency: US Dollar USD
8.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Adage Capital Management LPas of 31 Dec 2025 | 7.08m | 1.95% |
| Deep Track Capital LPas of 31 Dec 2025 | 4.68m | 1.29% |
| ARK Investment Management LLCas of 31 Dec 2025 | 3.31m | 0.91% |
| Morgan Stanley Investment Management, Inc.as of 31 Dec 2025 | 2.87m | 0.79% |
| Marshall Wace LLPas of 31 Dec 2025 | 2.68m | 0.74% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 2.27m | 0.62% |
| RTW Investments LPas of 31 Dec 2025 | 2.00m | 0.55% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 1.85m | 0.51% |
| Columbia Management Investment Advisers LLCas of 31 Dec 2025 | 1.74m | 0.48% |
| Eagle Health Investments LPas of 31 Dec 2025 | 1.68m | 0.46% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
